Cardiovascular and Venous Thromboembolic Risk With Janus Kinase Inhibitors in Immune‐Mediated Inflammatory Diseases: A Systematic Review and Meta‐Analysis of Randomized Trials

Cardiovascular and Venous Thromboembolic Risk With Janus Kinase Inhibitors in Immune‐Mediated Inflammatory Diseases: A Systematic Review and Meta‐Analysis of Randomized Trials

Objective Janus kinase (JAK) inhibition effectively treats immune‐mediated inflammatory diseases (IMIDs); however, concern over the risk of major adverse cardiac events (MACE) and venous thromboembolism (VTE) remains. We aimed to evaluate the safety (VTE and MACE outcomes) of JAK inhibitors in the t...

Full description

Bibliographic Details
Main Authors: Muhammad Haisum Maqsood, Brittany N. Weber, Rebecca H. Haberman, Kristen I. Lo Sicco, Sripal Bangalore, Michael S. Garshick
Format: Article
Language:English
Published: Wiley 2022-10-01
Series:ACR Open Rheumatology
Online Access:https://doi.org/10.1002/acr2.11479

Similar Items

Similar Items